Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Amgen's Osteoporosis Candidate Evenity Gets Approval In Japan

By Zacks Investment ResearchStock MarketsJan 08, 2019 09:50PM ET
www.investing.com/analysis/amgens-osteoporosis-candidate-evenity-gets-approval-in-japan-200374034
Amgen's Osteoporosis Candidate Evenity Gets Approval In Japan
By Zacks Investment Research   |  Jan 08, 2019 09:50PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

Amgen, Inc. (NASDAQ:AMGN) and its partner UCB announced that its osteoporosis candidate, Evenity (romosozumab) has gained marketing approval in Japan, the first regulatory approval for the pipeline product. Evenity has been approved In Japan to reduce the risk of fractures and increase bone mineral density in men and postmenopausal women with osteoporosis at high risk of fracture.

Evenity is also under review in United States and Europe. In the United States, Amgen re-submitted the biologics license application (“BLA”) in July last year. The first BLA seeking approval of Evenity for the same indication in the United States was issued a complete response letter (“CRL”) by the FDA in July 2017. The CRL was issued due to a cardiovascular side effect observed in the ARCH study. The first BLA included data only from FRAME study. The FDA requested a resubmission of the application with additional data from the ARCH and the BRIDGE studies. The second BLA includes data from the ARCH and BRIDGE studies.

In November, Amgen had informed that the FDA’s Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) will review the BLA for Evenity on Jan 16, 2019.

In Japan, the development of Evenity is being led by Astellas BioPharma, a joint venture between Amgen and Japanese drug company, Astellas Pharma.

In the past year, Amgen’s stock has risen 9.7% against 21.2% decrease of its industry.

Separately, Amgen announced that all device options of its PCSK9 inhibitor, Repatha including pre-filled syringe and the Pushtronex system are now available in the United States at a discount of 60%. The products are now available at a reduced list price of $5,850 per year.

Amgen announced its decision to cut the U.S. list price of Repatha by 60% in October last year to improve access and affordability of Repatha. Please note that Repatha SureClick autoinjector, the most popular device option of Repatha, has been available at a discounted price since Oct 24 last year.

Sales of the drug have suffered since launch due to payer restrictions. At the third quarter conference call held in October, Amgen had said that despite its efforts to improve access to Repatha, patients still face significant hurdles due to high co-pay expenses. Though lower price may impact Repatha sales in the near term, management is optimistic about better volumes.

Amgen currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Some better-ranked stocks in the biotech sector are Aeterna Zentaris Inc. (TO:AEZS) , Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) and Inovio Pharmaceuticals, Inc. (NASDAQ:INO) , all sporting a Zacks Rank #1.

Estimates for Aeterna Zentaris have been revised from a loss of 37 cents to earnings of 2 cents for 2019 over the past 60 days. The stock has soared 48.9% in the past year.

Vanda’s earnings estimates have moved 11.1% north for 2019 over the past 90 days. The stock has surged 106.5% in a year.

Inovio’s loss estimates have remained unchanged in the past 60 days. The stock has risen 9.2% in a year.

Today's Stocks from Zacks' Hottest Strategies

It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.

And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.

See Them Free>>



Amgen Inc. (AMGN): Free Stock Analysis Report

Vanda Pharmaceuticals Inc. (VNDA): Free Stock Analysis Report

Inovio Pharmaceuticals, Inc. (INO): Free Stock Analysis Report

AEterna Zentaris Inc. (AEZS): Free Stock Analysis Report

Original post

Zacks Investment Research
Amgen's Osteoporosis Candidate Evenity Gets Approval In Japan
 

Related Articles

Amgen's Osteoporosis Candidate Evenity Gets Approval In Japan

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email